SLU7: A Potential Drug Target or Biomarker (G10569)

Target Name: SLU7

NCBI ID: G10569

SLU7

SLU7: A Potential Drug Target or Biomarker

SLU7 (SLU7_HUMAN) is a protein that is expressed in a variety of human tissues and has been identified as a potential drug target or biomarker. The protein is located in the endoplasmic reticulum and is involved in the regulation of cellular processes that are important for the development, maintenance, and progression of various diseases, including cancer.

SLU7 is a member of the protein family known as the long non-coding RNA (lncRNA) family. This family of genes has been implicated in the regulation of gene expression and has been implicated in the development and progression of various diseases. The lncRNA family is characterized by the presence of a long non-coding RNA molecule that can interact with a variety of factors, including other proteins and small molecules.

SLU7 has been shown to play a role in the regulation of cellular processes that are important for the development, maintenance, and progression of various diseases, including cancer. For example, studies have shown that SLU7 can be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis, all of which are important processes that are involved in the development and progression of cancer.

In addition to its role in cellular processes, SLU7 has also been shown to be involved in the regulation of cellular signaling pathways. For example, studies have shown that SLU7 can interact with the protein known as PDGFRA and can regulate the activity of the PDGF signaling pathway. This suggests that SLU7 may be a potential drug target or biomarker for diseases that are characterized by the over-expression or deregulation of the PDGF signaling pathway.

Another study has also shown that SLU7 can be regulated by the protein known as NF-kappa-B, which is a transcription factor that plays a role in the regulation of cellular processes that are important for the development, maintenance, and progression of various diseases, including cancer. This suggests that SLU7 may be a potential drug target or biomarker for diseases that are characterized by the over-expression or deregulation of the NF-kappa-B signaling pathway.

In conclusion, SLU7 is a protein that has been shown to play a role in the regulation of cellular processes that are important for the development, maintenance, and progression of various diseases, including cancer. The protein is located in the endoplasmic reticulum and has been shown to interact with a variety of factors, including PDGFRA, NF-kappa-B, and other proteins. These interactions suggest that SLU7 may be a potential drug target or biomarker for diseases that are characterized by the over-expression or deregulation of these signaling pathways. Further research is needed to fully understand the role of SLU7 in the development and progression of various diseases.

Protein Name: SLU7 Homolog, Splicing Factor

Functions: Required for pre-mRNA splicing as component of the spliceosome (PubMed:10197984, PubMed:28502770, PubMed:30705154). Participates in the second catalytic step of pre-mRNA splicing, when the free hydroxyl group of exon I attacks the 3'-splice site to generate spliced mRNA and the excised lariat intron. Required for holding exon 1 properly in the spliceosome and for correct AG identification when more than one possible AG exists in 3'-splicing site region. May be involved in the activation of proximal AG. Probably also involved in alternative splicing regulation

The "SLU7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLU7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets